Claims for Patent: 10,016,365

Summary for Patent: 10,016,365

Title:	Compositions and methods of tumor treatment utilizing nanoparticles
Abstract:	The present invention is directed to a method for treating cancer intraperitoneally in a subject. The method comprises administering to said subject in need thereof an anti-cancer agent encapsulated in nanoparticles wherein nanoparticles are characterized to slowly release anti-cancer agent in a timely fashion that allows efficient killing of tumor cells. The nanoparticles described herein are characterized to slowly release anti-cancer agent at a rate of 30% or less per 24 hours based on in vitro drug dissolution study.
Inventor(s):	Chuang; Chi-Mu (Taipei, TW), Chang; Chi-Tai (Taipei, TW)
Assignee:	OP NANO CO., LTD. (Taipei, TW) TRENDMED CO., LTD. (Beitou Dist., Taipei, TW)
Application Number:	15/550,786
Patent Claims:	1. A method for treating cancer in a subject comprising administering to said subject intraperitoneally in need thereof an anti-cancer agent encapsulated in nanoparticles, wherein said nanoparticles are liposomes, and wherein said nanoparticles comprise all of hydrogenated soy phosphatidylcholine, cholesterol and d-alpha-tocopheryl polyethylene glycol succinate, and wherein said nanoparticles slowly release anti-cancer agent at a rate of 30% or less per 24 hours based on in vitro drug dissolution. 2. The method of claim 1 wherein said anti-cancer agent is selected from the group consisting of gemcitabine, idarubicin/cytarabine, etopside phosphate, gleevec, temozolomide, bortezomib, letrozole, cetuximab, bevacizumab, paclitaxel, nab-paclitaxel, docetaxel, erlotinib, pemetrexed, pemetrexed/carboplatin, paxlitaxel/carboplatin, letrozole/cyclophsphamide, temsirolimus, bevacizumab/temsirolimus, Ipilimumab, RAD001, Pazopanib, FOLFIRI, BKM120, GSK1120212, PF-05212384/irinotecan, AZD2171, PF-04691502, cyclophosphamide, cisplatin, cytarabine/daunorubcin, tersirolimus, erlotinib/temsirolimus, capecitabine, tamoxifen, bortezomib, trastuzumab, docetaxel/capecitabine, trastuzumab/tipifarnib, tipifarnib/gemcitabline, tootecan, and combinations thereof. 3. The method of claim 2, wherein said anti-cancer agent is paclitaxel. 4. The method of claim 1 wherein said cancer is ovarian cancer, lung cancer, liver cancer, gastric cancer, or colon cancer. 5. The method of claim 4, wherein said cancer is ovarian or colon cancer. 6. A method for treating cancer via regional delivery in a subject comprising administering intrapleurally to said subject in need thereof an anti-cancer agent encapsulated in sustained release nanoparticles, wherein said nanoparticles are liposomes, and wherein said nanoparticles comprise all of hydrogenated soy phosphatidylcholine, cholesterol and d-alpha-tocopheryl polyethylene glycol succinate wherein the anti-cancer agent nanoparticles slowly release anti-cancer agent at a rate of 30% or less per 24 hours based on in vitro drug dissolution. 7. The method of claim 6, wherein the cancer is ovarian cancer, lung cancer, liver cancer, gastric cancer, or colon cancer. 8. The method of claim 7, wherein the cancer is metastasis. 9. The method of claim 6, wherein said subject has severe adhesion in the peritoneal cavity. 10. The method of claim 6, wherein said anti-cancer agent is paclitaxel.

Details for Patent 10,016,365

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2039-02-26
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-02-26
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2039-02-26